Clinuvel Pharmaceuticals (UR9) Price & Analysis

0 Followers

UR9 Stock Chart & Stats

CHF5.74

CHF0.00(0.00%)

At close: Jul 24 4:00 PM EDT

CHF5.74

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF4.63 - CHF6.26

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

CHF236.59M

Enterprise ValueCHF272.15

Total Cash (Recent Filing)CHF252.06M

Total Debt (Recent Filing)CHF1.94M

Price to Earnings (P/E)12.4

Beta3.06

Next Earnings

Feb 23, 2027

EPS Estimate

0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.68

Shares Outstanding50,427,900

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-2.72

Price to Book (P/B)1.88

Price to Sales (P/S)5.45

P/FCF Ratio14.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF9.90

Price Target Upside72.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)0.4

Revenue Forecast (FY)CHF55.31M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet And Growing LiquidityMinimal leverage and substantial cash reserves reduce financial risk, support continued investment in clinical and manufacturing capabilities, and provide funding flexibility without near-term dependence on debt or equity issuance.

Sustained Profitability And Strong Cash ConversionLong-running profitability and operating cash flow above net income indicate a commercially proven business with high earnings quality. This supports self-funded growth and gives management resilience while expanding development activities.

Expanding Commercial Footprint Supports Product DemandHigher permitted treatment frequency in Europe and broader North American site coverage expand SCENESSE’s addressable treated population. These structural distribution and access improvements can support recurring sales growth beyond a single reporting period.

Bears Say

Revenue Decline And Gross-margin ResetThe return to negative revenue growth and weaker gross margin may indicate pricing, product-mix, or cost pressure. If sustained, these trends could reduce operating leverage and weaken the earnings power supporting future investment.

Rapid Expense Growth Pressures Operating LeverageInvestment in personnel, clinical programs, distribution, and corporate infrastructure may build long-term capabilities, but spending is currently growing faster than sales. Persistent cost escalation could compress margins and delay improvement in free cash flow.

Clinical And Regulatory Timelines Create Execution RiskThe requirement to complete multiple studies before seeking approvals delays potential diversification beyond SCENESSE’s current indications. Longer timelines increase development costs and leave future growth dependent on successful clinical and regulatory execution.

Clinuvel Pharmaceuticals News

Clinuvel Unveils ZEROKIN Single-Use Device for Controlled-Release Drug Delivery

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an announcement. On 8 September 2026, Clinuvel Pharmaceuticals announced it had...

6d ago

Clinuvel Unveils ZEROKIN Device to Target Growing Self-Injection Market

The latest announcement is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has completed development of ZEROKIN,...

8d ago

Vanguard Drops Below Substantial Holder Threshold in Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Vanguard Group, including its controlled entities such as Vanguard...

14d ago

Clinuvel Weighs Nasdaq-Only Listing as Headquarters Shift to U.S.

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an update. Clinuvel Pharmaceuticals’ board is evaluating a restructuring that would...

20d ago

Clinuvel Flags Key Risks as It Builds U.S.-Led Expansion

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals has outlined its risk landscape as it...

20d ago

Clinuvel Confirms ASX Governance Compliance With 2026 Appendix 4G Filing

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an announcement. Clinuvel Pharmaceuticals has lodged its Appendix 4G with the...

20d ago

Clinuvel Affirms ASX Governance Compliance and Highlights Diversity Gains

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an update. Clinuvel Pharmaceuticals has released its corporate governance statement for...

20d ago

Clinuvel Declares AUD 0.05 Dividend for FY2026

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company listed...

20d ago

Clinuvel Leverages Decade of Profits to Fund U.S. Expansion Despite Flat FY2026 Revenue

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals reported its tenth consecutive annual profit for...

20d ago

Clinuvel Sets Investor Webinar to Unveil 2026 Annual Results

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals will release its annual financial results for...

27d ago

UR9 FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest stock price was CHF4.63 and its highest was CHF6.26 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is CHF236.59M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Feb 23, 2027 which is in 161 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Aug 27, 2026. The company reported CHF0.273 earnings per share for the quarter, missing the consensus estimate of CHF0.291 by -CHF0.018.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited does not currently pay dividends.

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.15.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,427,900 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of CHF0.273 in its last earnings report, missing expectations of CHF0.291. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in CH:UR9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

0.74%

Trailing 12-Months

Asset Growth

14.85%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Clinuvel Pharmaceuticals (UR9) Earnings & Revenues

Historic Earnings Reports

UR9 Company Deck

UR9 Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all CH:UR9 earnings summaries

UR9 Stock 12 Month Forecast

Average Price Target

CHF9.90

▲(72.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"CHF4","23":"CHF23","8.75":"CHF8.75","13.5":"CHF13.5","18.25":"CHF18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.962246837,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF22.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.9035644755,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF9.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5623559768,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF5.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.75,13.5,18.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.715,7.041711295153846,8.368422590307691,9.695133885461537,11.021845180615383,12.348556475769229,13.675267770923076,15.001979066076922,16.32869036123077,17.655401656384612,18.98211295153846,20.308824246692303,21.635535541846153,{"y":22.962246837,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.715,6.037197267346154,6.359394534692307,6.6815918020384615,7.003789069384615,7.325986336730769,7.648183604076923,7.970380871423076,8.29257813876923,8.614775406115385,8.936972673461538,9.259169940807691,9.581367208153846,{"y":9.9035644755,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.715,5.703258152061538,5.691516304123077,5.6797744561846155,5.668032608246154,5.656290760307693,5.644548912369231,5.632807064430769,5.621065216492307,5.609323368553846,5.5975815206153845,5.585839672676923,5.574097824738462,{"y":5.5623559768,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.715,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >